Correlation Analysis of Neuropathic Headache and Depression and Anxiety

Objective:To explore the relationship between neuropathic headache,and depression and anxiety,as well as to adopt reasonable methods to reduce patients'depression and anxiety.Methods:From June 2019 to May 2021,a total of 89 neuropathic headache patients were treated in our hospital,which is Yidu Central Hospital of Weifang and they were recorded as the observation group.During the same period,healthy individuals were randomly selected using a random number table method and 91 cases were randomly selected and recorded as the control group.Through the questionnaire survey and the use of SAS and SDS scores,the anxiety and depression of healthy people were evaluated,and the correlation between neurological headache,and anxiety and depression were analyzed.Results:In the control group,the number of people with mild,moderate,and severe anxiety were three,two,and zero,accounting for 3.30%,2.20%,and 0.00%,respectively.The total anxiety was 5.50%,and the SAS score was 31.23±3.22;In the observation group,the number of people with mild,moderate,and severe anxiety were fourteen,eleven,and six,accounting for 15.73%,12.36%,and 6.74%,respectively.The total anxiety was 34.83%,and the SAS score was 49.56±4.98,which was measured.The data shows that the control group is significantly lower than the observation group in terms of the number of people or the anxiety score,and both P<0.05 are statistically significant;the number of mild,moderate,and severe depression in the control group is four,two,and zero,respectively.They were 4.40%,2.20%,0.00%,the total depression was 6.60%,and the SAS score was 33.23±3.24;the number of people with mild,moderate,and severe depression in the observation group were sixteen,eleven,and five,respectively.17.98%,12.36%,5.62%,total depression degree was 35.96%,SAS score was 46.56±4.68.The measurement data showed that the control group was significantly lower than the observation group in terms of the number of people or the depression score,and both were P<0.05,which was statistically significant.Conclusion:Patients with neuropathic pain are usually accompanied by anxiety and depression.Anxiety and depression are also important factors that affect patients with neuropathic pain.Psychotherapy intervention for patients is very necessary to relieve patients'anxiety and depression.Thereby reducing the pain of the patient.

Guanxin Danshen Dripping Pills Improve Quality of Life and Cardiovascular Prognoses of CHD Patients after PCI with Anxiety or Depression(GLAD Study):A Randomized Double-Blind Placebo-Controlled Study

Objective:To assess the efficacy and safety of Guanxin Danshen Dripping Pills(GXDS)in the treatment of depression or anxiety in patients with coronary heart disease(CHD)after percutaneous coronary intervention(PCI).Methods:From September 2017 to June 2019,200 CHD patients after PCI with depression and anxiety were included and randomly divided into GXDS(100 cases)and placebo control groups(100 cases)by block randomization and a random number table.Patients in the GXDS and control groups were given GXDS and placebo,respectively,0.4 g each time,3 times daily for 12 weeks.The primary outcomes were scores of Patient Health Questionnaire-9(PHQ-9),Generalized Anxiety Scale(GAD-7)and the Seattle Angina Pectoris Scale(SAQ).The secondary outcomes included 12 Health Survey Summary Form(SF-12)scores and the first onset time and incidence of major adverse cardiovascular events(MACEs).Other indices including blood pressure,blood lipids,microcirculation and inflammatory-related indices,etc.were monitored at baseline,week 4,and week 12.Results:In the full analysis set(200 cases),after treatment,the PHQ-9 and GAD-7 scores in the GXDS group were considerably lower than those in the control group(P<0.05).Compared with the baseline,the total PHQ-9 scores of the experimental and control groups decreased by 3.97 and 1.18,respectively.The corrected mean difference between the two groups was–2.78(95%CI:–3.47,–2.10;P<0.001).The total GAD-7 score in the GXDS group decreased by 3.48%compared with the baseline level,while that of the placebo group decreased by 1.13%.The corrected mean difference between the two groups was–2.35(95%CI:–2.95,–1.76;P<0.001).The degree of improvement in SAQ score,SF-12 score,endothelin and high-sensitive C-reactive protein levels in the GXDS group were substantially superior than those in the placebo group,and the differences between the two groups were statistically significant(P<0.05).Similar results were obtained in the per protocol population analysis of 177 patients.Three cases of MACES were reported in this study(1 in the GXDS group and 2 in the placebo group),and no serious adverse events occurred.Conclusions:GXDS can significantly alleviate depression and anxiety,relieve symptoms of angina,and improve quality of life in patients with CHD after PCI.(Registration No.ChiCTR1800014291)

The trade-off between COVID-19 and mental diseases burden during a lockdown: Mathematical modeling of control measures

Background:During the COVID-19 pandemic,many countries used lockdowns as a containment measure.While lockdowns successfully contributed to slowing down the contagion,the related mobility restrictions were reportedly associated with an increased risk of major depressive and anxiety disorders.We aimed to quantify the trade-off between the quality-adjusted life years(QALY)gain due to lower COVID-19 incidence as a result of a lockdown and QALY loss due to lockdown-induced mental disorders.Methods:We developed an agent-based model of COVID-19 epidemic and coupled mental disorder development in the population of a large city.We used data sources on the places of living,studying and working,public health and census surveys.Modeling of mental disorders was based on diathesis-stress concept.We quantified mental and physical health burden in terms of QALY taking into account major depressive and anxiety disorder episodes,lethal and non-lethal cases of COVID-19,and immunization.Findings:We evaluated the dynamics of new major depressive disorder(MDD)and anxiety disorder(AD)cases during the period between September 2020 and December 2021 in Moscow,Russia.We found that lockdown imposition increases the daily chances of getting MDD or ADD by a vulnerable person by 16.79%(95%CI[12.36%,21.23%]).The QALY loss associated with COVID-19-induced and lockdown-induced mental disorders was estimated to be 18.93%(95%CI[16.94%,19.73%])of the total QALY loss caused by COVID-19,immunization,and all kinds of mental disorders.For a synthetic“strong”lockdown,it had been shown that QALY loss is minimized when about 70%of the population are isolated.Interpretation:The burden associated with mental disorders amounts to a considerable part of COVID-19-related losses.Our findings demonstrate that cost-benefit analysis of mobility restriction should include a forecast of mental disorder development in the population.